PharmaDrug Inc CEO Daniel Cohen tells Proactive the group announced a positive research result for its preclinical cancer study which evaluated the effectiveness of cepharanthine-2HCI alone or when used in combination with standard of care (SoC) chemotherapy on four undisclosed cancer types.
The company said that it is now focusing on advancing Investigational New Drug enabling studies to support future FDA clinical studies in 2022 for cepharanthine. Cohen says moving research from in vitro (cell culture-based models) into accepted animal models of cancer is a critical step along its path to the clinic.